Oncternal Therapeutics to Present Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with Ibrutinib at the 2019 American Society of Clinical Oncology Annual Meeting

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing